38results about How to "Inhibit lipid accumulation" patented technology

The present invention provides a pharmaceutical composition having at least one kind to be selected from the group consisting of a lactoferrin group protein comprising lactoferrin and conalbumin, and an enzymatically decomposed product of the lactoferrin group protein comprising peptides corresponding to lactoferricin and lactoferricin of conalbumin an active ingredient. The composition of the present invention can be used as an agent for improving lipid metabolism. Further, it is useful for treating hypercholesterolemia, hyper-neutral lipidemia, hyper-low density lipoprotein (LDL) cholesterolemia, hypo-high density lipoprotein (HDL) cholesterolemia, obesity, fatty liver and cholesterol gallstone and lifestyle-related diseases such as severe obesity, hyperlipidemia, hypertension and type II diabetes. The composition of the present invention can improve basal metabolic rate.

Cyclodextrin compound therapeutics to reduce age-related non-bisretinoid lipofuscin in a patient having a buildup of same, said method comprising administering 2-hydroxypropyl-β-cyclodextrin, or its derivatives, or β-cyclodextrin or its derivatives, or α-cyclodextrin or its derivatives, or γ-cyclodextrin or its derivatives in an amount effective to reduce non-bisretinoid lipofuscin levels. The methods include treating and/or preventing aging of the skin, muscle and other tissues and organs, which may result in increased life-span or health-span.

The present invention relates to edible compositions for the maintenance of normal liver function comprising zinc, 1-deoxynojirimycinand α-lipoic acid.

The present invention relates to a fat absorption inhibitor containing a chestnut skin extract, and a food and drink containing that fat absorption inhibitor. The present invention can therefore provide a fat absorption inhibitor, and a food and drink using the same, that can be obtained from waste products following primary use, inhibit increases in lipids such as blood neutral fats by inhibiting absorption of dietary lipids, and in turn are effective in preventing accumulation of lipids, have superior suitability for continuous ingestion without having an impact on flavor, and do not require a complex production process.

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

The invention belongs to the technical field of feed processing, and particularly relates to a golden pomelo young fruit polysaccharide-containing grouper feed and a preparation method thereof. The golden pomelo young fruit polysaccharide-containing grouper feed not only can improve the oxidation resistance and immunity of pearl gentian groupers, but also can inhibit lipid accumulation of the pearl gentian groupers and improve the liver structure and liver pathological damage degree, and is free of toxic and side effects and environmentally friendly. Meanwhile, the grouper feed containing the golden pomelo young fruit polysaccharide is low in vitamin loss rate when being put into a water body, the vitamin content in the feed can be well maintained, the vitamin absorption of the pearl-gentian grouper is ensured, and the growth and reproduction of the grouper are more facilitated.

The invention relates to a human leukocyte protease inhibitory factor as well as recombinant preparation and an application thereof, which belong to the field of biological medicines. The amino acid sequence contained in the human leukocyte protease inhibitory inhibitor is as follows: (1) an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; (2) an amino acid sequence obtained by connecting a label to the N end or/and C end of the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; and (3) an amino acid sequence which is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 or SEQ ID NO: 3 and has the activity of the human leukocyte protease inhibitory factor. The preparation method comprises the following steps: constructing plasmids, carrying out inducible expression to obtain fusion protein, purifying, and carrying out renaturation concentration. The protein provided by the invention has important application in preparation of drugs for treating metabolic diseases, and can reduce weight, inhibit increase of adipose tissue weight and inhibit liver fatty degeneration.

The invention provides an application of rosustat in a medicine for inhibiting acute alcoholic fatty liver. Roxasstat can significantly inhibit liver injury and lipid accumulation caused by acute alcohol. According to the mechanism, rosustat plays a role in inhibiting mouse liver lipid accumulation mainly by regulating and controlling the expression of lipid synthesis key genes. The medicine is expected to become an effective medicine for clinically treating the alcoholic fatty liver.

An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

The invention discloses application of malonic-acid-modified fullerene C70 in preparation of a medicine for treating the non-alcoholic fatty liver disease. The medicine that uses the C70-malonic acidderivative as the active ingredient and is used for preventing, relieving and/or treating the non-alcoholic fatty liver disease and related diseases has the following advantages: firstly, the pharmacodynamic effect is obvious, the C70-malonic acid derivative can obviously inhibit lipid accumulation in primary hepatocytes of mice and obvious changes can be seen in 10 micrometers; in addition, the C70-malonic acid derivative also has an obvious improvement effect on liver lipid accumulation and fibrosis generated by HFHC diet induction; secondly, the malonic-acid-modified fullerene C70 can effectively reduce the damage of a carbon cage in a fullerene modification process, so that the pharmacodynamic activity of the fullerene body is better retained; and thirdly, the C70-malonic acid derivative has a determined molecular structure, problems that other water-soluble fullerene derivatives have no determined structure and are difficult in quality control are solved, and the patent medicine is realized conveniently.

The present invention is related to a pharmaceutical composition and a dietary supplement for treating and preventing obesity, containing a wheatgrass extract as an active ingredient, it has been ascertained that the wheatgrass extract shows excellent anti-obesity effects such as significant inhibition of weight gain caused by a high fat diet, or lowering of neutral lipid levels in blood in a high fat diet-induced animal model. The wheatgrass extract of the present invention can be useful as a pharmaceutical composition and a dietary supplement for preventing and treating obesity.

The invention discloses application of sorafenib to preparing a medicine for preventing, alleviating and/or treating fatty liver and related diseases, and belongs to novel application of the medicineof the sorafenib. The medicine taking the sorafenib as the active ingredient and used for preventing, alleviating and/or treating fatty liver and related diseases has the following advantages: 1, thesorafenib belongs to a medicine approved by U.S.FDA, and therefore, the existing huge toxicity and dosage data of the medicine are utilized, and a large amount of time and a large number of financialresources are saved; and 2, the curative effect is obvious, the sorafenib obviously inhibits the accumulation of lipid in a cell L02, and the obvious change is seen when the pretreatment concentrationof the sorafenib is 2 [mu]mol; when the pretreatment concentration of the sorafenib is 6 [mu]mol, the sorafenib is detected to obviously inhibit the accumulation of the lipid in the primary hepatocyte of a mouse; and in addition, the sorafenib has an obvious effect of inhibiting the accumulation of the lipid caused by the induction of the HFHC (High Fat and High Cholesterol) diet. The sorafenib has a broad application prospect in the medical field.

Proposed is a Geumhwagyu extract as an active ingredient. The Geumhwagyu extract of the present disclosure inhibits the differentiation of pre-adipocytes by inducing the degradation of CEBP-α and inhibits the expression of CEBP-α, PPARγ, Perilipin-1, Adiponectin, FABP4, etc., to suppress the accumulation of lipids in adipocytes. It can be easily used as a composition for preventing or managing obesity by inhibiting it and lowering the content of TG (Triacylglycerol) to show anti-obesity activity.

The invention provides Bifidobacterium pseudocatenatum and application thereof in metabolic syndrome, and relates to the field of microorganisms. The preservation number of the Bifidobacterium pseudocatenatum is CGMCC No.22185, the Bifidobacterium pseudocatenatum is preserved in China General Microbiological Culture Collection Center on April 14, 2021, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing. According to the Bifidobacterium pseudocatenatum, the accumulation of liver cell lipid can be significantly inhibited, the body weight and the blood fat level can be reduced, the liver fatty degeneration can be further improved, and the important application significance can be provided for the alleviation of the occurrence of hyperlipidemia, obesity and fatty liver.